198 related articles for article (PubMed ID: 25993199)
1. Hematopoietic cell transplantation for myelodysplastic syndrome.
Deeg HJ
Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
6. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
7. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wu B; Wei Y; Zhang Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
Marcondes M; Deeg HJ
Best Pract Res Clin Haematol; 2008 Mar; 21(1):67-77. PubMed ID: 18342814
[TBL] [Abstract][Full Text] [Related]
9. Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.
Kröger N
Semin Hematol; 2017 Jul; 54(3):154-158. PubMed ID: 28958289
[TBL] [Abstract][Full Text] [Related]
10. Transplantation for myelodysplastic syndromes 2013.
Vaughn JE; Scott BL; Deeg HJ
Curr Opin Hematol; 2013 Nov; 20(6):494-500. PubMed ID: 24104409
[TBL] [Abstract][Full Text] [Related]
11. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.
Deeg HJ; Bartenstein M
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):31-41. PubMed ID: 22143157
[TBL] [Abstract][Full Text] [Related]
13. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
Warlick ED
Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
Bhatt VR; Steensma DP
J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ
Br J Haematol; 2006 Oct; 135(2):201-9. PubMed ID: 16939494
[TBL] [Abstract][Full Text] [Related]
17. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
Finke J; Nagler A
Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
[TBL] [Abstract][Full Text] [Related]
18. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
19. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]